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Abstract
Background: Standard logistic regression with or without stepwise selection has the disadvantage of not
incorporating model uncertainty and the dependency of estimates on the underlying model into the final
inference. We explore the use of a Bayes Model Averaging approach as an alternative to analyze the influence of
genetic variants, environmental effects and their interactions on disease.
Methods: Logistic regression with and without stepwise selection and Bayes Model Averaging were applied to a
population-based case-control study exploring the association of genetic variants in tobacco smoke-related
carcinogen pathways with breast cancer.
Results: Both regression and Bayes Model Averaging highlighted a significant effect of NAT1*10 on breast cancer,
while regression analysis also suggested a significant effect for packyears and for the interaction of packyears and
NAT2.
Conclusions: Bayes Model Averaging allows incorporation of model uncertainty, helps reduce dimensionality and
avoids the problem of multiple comparisons. It can be used to incorporate biological information, such as pathway
data, into the analysis. As with all Bayesian analysis methods, careful consideration must be given to prior
specification.
Background
Logistic regression and regression with stepwise selection
are standard approaches to assess individual and joint
effects of genetic and environmental factors on disease
risk. However, one drawback is that the resulting estimates
depend on the choice of the underlying causal model, and
that hence a different set of covariates may lead to differ-
ent effect estimates and potentially a different pattern of
significance. Moreover, standard regression approaches do
not incorporate the uncertainty about our choice of the
assumed causal model into the final inference.
An alternative approach to analyze such data in com-
bination is Bayes Model Averaging (BMA) [1], which
explicitly accounts for uncertainty with respect to the
causal model. BMA specifies prior distributions for
model parameters and uses Markov Chain Monte Carlo
(MCMC) methods to infer posterior estimates from the
priors and from the data. Its inherent model selection
feature evaluates different submodels and inference is
obtained by averaging over all models considered. By
selecting and evaluating a range of submodels, BMA
provides a means to reduce dimensionality in the pre-
sence of many predictors, when including all variables
and their pairwise or higher-order interactions into a
logistic model might lead to unstable estimates and bias
due to sparse data and correlation [2]. Model selection
methods like stepwise regression achieve a similar goal,
but do so in a mechanical way, often leading to globally
suboptimal and unstable estimates.
We applied both BMA and logistic regression with
and without stepwise selection to data from a case-con-
trol study exploring the association of genetic variants
in the cigarette smoke carcinogen metabolism and
breast cancer. Cigarette smoke is known to contain aro-
matic amines and polycyclic aromatic hydrocarbons,
whose conversion to reactive metabolites by catalyzing
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breast carcinogenesis. The present population-based
case-control study of breast cancer in Germany evalu-
ated the role of genetic polymorphisms in Phase I and II
enzymes NAT1 and NAT2 in the AA pathway and
CYP1A1, CYP1B1, GSTM1 and GSTT1 in the PAH
pathway and cigarette smoke exposure in breast carcino-
genesis. We analyzed pairwise interactions of poly-
morphisms as well as interactions of smoking and the
polymorphisms to determine an effect on breast cancer
risk. The postulated pathways are depicted as a directed
acyclic graph in Figure 1.
Methods
Data
Data were derived from a population-based matched
case-control study on breast cancer conducted in the
study regions “Rhein-Neckar-Odenwald” and “Freiburg”
of Southern Germany between 1992 and 1995, as
described previously [3,4]. Cases were diagnosed by age
50 with invasive or in-situ breast cancer, and two
controls were matched to cases by age at diagnosis
and study region. Participants completed a self-adminis-
tered questionnaire assessing demographic factors,
anthropometric measures and other known or putative
risk factors, including smoking history. All study partici-
pants gave written informed consent, and the study was
reviewed and approved by the ethics committee of the
University of Heidelberg, Heidelberg, Germany.
Smoking behavior was assessed over a lifetime,
accounting up to eight different phases of active smok-
ing habits. Cumulative cigarette smoking was quantified
in packyears, defined as the number of packs of cigar-
ettes smoked per day multiplied by the number of years
the individual has smoked.
For the present study we analyzed polymorphisms in the
genes NAT1, NAT2, CYP1A1, CYP1B1,a sw e l la st h e
GSTM1 and GSTT1 deletion polymorphisms. Specifically,
NAT1 and CYP1B1 genotypes were coded as the number
of NAT1*10 and CYP1B1*3 alleles, respectively. NAT2 was
coded rapid acetylating conditional on the presence of at
least one NAT2*4 allele, which is characterized by the
absence of four point mutations (as previously described
in [3]), and slow acetylating otherwise. CYP1A1 was either
homozygote for the wild-type allele CYP1A1*1, defined by
the absence of three point mutations (rs1056827,
rs1056836, rs1800440), or otherwise. GSTM1 and GSTT1
were characterized by the absence of their gene product.
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Figure 1 Directed Acyclic Graph of the proposed pathways. Measured quantities, i.e. smoking, disease status and genotypes are represented
by angular boxes, intermediate metabolites by rounded boxes. Solid arrows mark the metabolic pathways whereas broken arrows indicate the
influence of the polymorphisms.
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cancer in terms of number of affected first-degree rela-
tives, and menopausal status classified as either pre- or
postmenopausal, or unknown for women with previous
hysterectomy not accompanied by bilateral oophorect-
omy. Menopausal status was assigned according to the
reported state a year before the reference date. Study
region showed no effect in an earlier analysis [5] and
was hence not considered in the model.
Non-missing genetic and epidemiologic data were
available for a total of 654 cases and 1085 controls. A
description of the study population and of the genetic
variables is given in Table 1.
Statistical Methods
General remarks
Interactions were only considered if all constituting
main effects were in the model. We further restricted
the domain of possible gene-gene interactions to
polymorphisms in the same pathway. All variables were
treated as continuous and were centered on 0.
Logistic regression and backward selection
All logistic regression models contained terms for age,
family history, and menopausal status. We tested (i)
main effects of smoking and the six polymorphisms
separately, (ii) interaction of smoking with each poly-
morphism, and (iii) gene-gene interactions for poly-
morphisms in the same pathway. Stepwise regression
with backwards selection was used to identify subsets of
variables that best explained the data according to the
Akaike Information Criterion [6]. We applied stepwise
regression to (i) the model containing smoking and
all six polymorphisms, and (ii) the model containing all
main effects as well as interactions of smoking with
all polymorphisms and all gene-gene interactions within
pathways.
Table 1 Study characteristics of the breast cancer case-control study in Germany and variable definition.
Variable Definition Levels Cases Controls
654 1085
Age 42.5 +/- 5.7 42.6 +/- 5.7
Family history first-degree relatives with breast cancer none 87.80% 94.80%
at least 1 12.20% 5.20%
Menopausal status
a premenopausal 78.70% 80.60%
postmenopausal 6.30% 6.50%
unknown 15.00% 12.90%
Smoking packyears over a lifetime 8.27 +/- 12.20 6.96 +/- 10.88
NAT1 number *10 alleles 0 64.10% 68.60%
1 32.30% 28.60%
2 3.70% 2.90%
CYP1B1 number *3 alleles 0 31.00% 28.90%
1 51.70% 50.90%
2 17.30% 20.20%
NAT2 presence of at least one *4 allele fast acetylator 43.70% 39.80%
slow acetylator 56.30% 60.20%
CYP1A1 homozygote for *1 allele Yes 75.80% 75.10%
No 24.20% 24.90%
GSTT1 absence of gene product No 84.30% 81.90%
Yes 15.70% 18.10%
GSTM1 absence of gene product No 45.70% 48.80%
Yes 54.30% 51.20%
a Women with a hysterectomy not accompanied by bilateral oophorectomy were classified as unknown
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The Bayesian model we used is illustrated as a directed
acyclic graph in Figure 2. At each iteration step, we con-
sidered a logistic model of the form
logit Pr( )| , YX X I X cc
c
= () =+ ∑∑ 1  

where {Xc} consisted of the terms for age, family his-
tory and menopause that were included in each model.
{Xν} contained the terms for smoking, the six poly-
morphisms, as well as interactions of smoking with all
polymorphisms, and all gene-gene interactions within
pathways. Following Conti et al. [1], Iν was a binary indi-
cator marking the presence of term Xν in the model.
Figure 2 Directed Acyclic Graph for BMA and its parameters. Boxes represent observed quantities, ovals parameters to be updated over the
course of MCMC, and rounded boxes fixed meta-parameters. Y denotes the dependent variable, and ν indexes the sets X of independent
predictor variables and b of corresponding estimates. I indicates inclusion of the νth variable and is Bernoulli-distributed with parameter pν,
which, in turn, follows a beta distribution with parameters (at,b t) depending on the interaction level t of the variable. The variance of the
coefficients bν is modeled by a residual variance term s
2 following a half-Cauchy prior, and a variance inflation factor ψt depending on the
interaction level and following a log-normal distribution with mean μt and variance τt.
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constituting main effects Xr and Xs, then Irs = 0 if any of
Ir or Is were 0, formalizing the requirement that all
main effects had to be in the model for an interaction
to be present.
The following prior distributions were specified
for the model parameters. The probability pν =
Pr(Iν = 1) was beta-distributed with parameters
 12 13
main main ,,    () = () if Xν was a main effect. This
prior corresponded to a marginal inclusion probability
of 0.25 for main effects and was chosen to reflect our
prior emphasis on models with fewer main effects.
Moreover, since the inclusion of interactions was lim-
ited by the hierarchical dependency on the presence of
the main effects, we encouraged inclusion of interac-
tion terms by specifying a greater marginal probability
of including term Xν = Xrs,p r o v i d e dt h a tIr = Is =1 .
Specifically, we set  12 22
int int ,,   () = () and there-
fore, the conditional prior probability of including
term Xrs was E(Irs =1 | Ir = Is =1 )=0 . 5 ,a n dt h em a r -
ginal prior probability was E(Irs = 1) = 0.03 = 0.25 ×
0.25 × 0.5.
A prior for the coefficients bν was specified via





~
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.
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I
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=
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Thus, if Iν =1 ,t h ev a r i a n c eo fbν was the product
of a fixed component s
2 and of a component
 t tm a i n i n t
2,   ∈{} , depending on whether Xν was a
main effect or an interaction. Specifically, we set
 main
2 1 = , such that s
2corresponded to the variance in
main effect coefficients, and  int
2 modeled the change in
that variance for interactions terms. To allow for updat-
ing via the Gibbs sampler when no interaction term was
present in the current model, a slightly informative prior
was chosen for  int
2 via log(ψint)~N(2.3,1).
An uninformative prior distribution was placed on s
2.
Since an inverse gamma prior, often chosen for the sake
of its conditional conjugacy, leads to improper posterior
distributions and sensitivity of inference to hyperpara-
meter choice [7], we specified a half-Cauchy prior distri-
bution with scale 100, as proposed by Gelman [7].
Note that via the above prior choices we a priori dis-
tinguished main and interaction effects via their model
inclusion probabilities and the assumed variance of their
coefficients. However, within these two groups variables
were treated as exchangeable due to lack of prior evi-
dence suggesting otherwise.
The approach was implemented using the software
WinBUGS [8], running 20,000 iterations and discarding
the first 2,000 as burn-in to ensure independence of the
results from the initial values. Another 2,000 iterations
were discarded through the default settings of Win-
BUGS to allow the Markov Chain to converge; hence
inference was based on 16,000 iterations. We visually
inspected plots of the sampled values to ensure conver-
gence of the chain (data not shown). WinBUGS code
for our analysis is provided [see Additional file 1].
Results
Logistic regression
Significant associations in univariate logistic regression
analysis were found for packyears and NAT1,a s
indicated by ORpackyears = 1.08, (p = 0.04, 95%-CI =
1.00-1.16) and ORNAT1 = 1.21, (p = 0.04, 95%-CI = 1.01-
1.44). We also tested interactions together with their
main effects and found evidence for the interaction of
packyears with NAT2 slow acetylator status (ORpackyears
× NAT2 = 1.19, p = 0.02, 95%-CI = 1.03-1.38). Estimates
did not change substantially when the model contained
all main effects (Modelmain in Table 2), or when all pair-
wise interactions (Modelall) were included. Regression
with backwards selection retained packyears, NAT1,
GSTM1 and CYP1B1 as explanatory variables when
applied to Modelmain, and in addition the interactions of
packyears with NAT2 and GSTM1 when applied to
Modelall (results not shown). For clarity, Table 2 only
tabulates interactions that showed positive findings from
any of the analysis approaches.
BMA
For BMA, posterior odds ratios and 95%-confidence
intervals (CI) were calculated based on the coefficients
bν across all models (marginal odds ratios) and across
all models with Iν = 1 (conditional odds ratios). We also
report the posterior probability that a variable is
included in the model, expecting that variables harbor-
ing an association with disease will be included more
frequently. Significance of findings was assessed via
Bayes factors (BF), the ratio of posterior to prior odds
that a variable was included in the model [9]. Thus eva-
luation of support of a non-zero coefficient took into
account the specified prior distribution. Two model
Bayes factors were computed in a similar fashion to
evaluate support of a selected model versus (i) compet-
ing models, and (ii) the null model.
In our prior specifications we emphasized sparse mod-
els, resulting in coefficient estimates of 0 for many
terms. Hence, expected values of marginal posterior
odds ratios showed considerable shrinkage towards 1
with tight confidence intervals due to the hierarchical
model (Table 2). The largest effect was observed for
NAT1 with ORNAT1 = 1.05 (95%-CI = 1.05-1.05). To
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sion we also tabulate expected odds ratios and confi-
dence intervals conditional on model inclusion. The
resulting values were similar to the three logistic regres-
sion scenarios, but again with much tighter confidence
intervals.
The latent indicator variable I was used to compute
the posterior probability of model inclusion for each
variable. The most frequently selected predictors were
NAT1 (Prposterior =0 . 2 6 ) ,NAT2 (Prposterior = 0.13) and
packyears (Prposterior = 0.13). The posterior probability
for the interaction term of packyears and NAT2 was
d e c r e a s e da t0 . 0 1 ,d u et ot h ea d ditional restriction that
both main effects had to be present in the model.
We used Bayes factors (BFs), the ratio of posterior and
prior odds that a variable was selected into the model,
to assess the significance of a result in relation to the
prior that had been assumed before the analysis. The
following calibration has been proposed by Kass and
Raftery [9] to interpret Bayes factors: between 1 and 3
suggests very mild evidence, between 3 and 20 positive
evidence, between 20 and 150 strong, and above 150
very strong evidence for an association. Based on these
guidelines, very mild evidence was found for NAT1
(BF = 1.05), while all other terms exhibited Bayes factors
below 1.
On the model level we first computed the Bayes factor
BFall for a specific model against all remaining models to
assess whether that model was superior to the compet-
ing models. Secondly, a Bayes factor BF0 was computed
comparing the model to the NULL model, measuring
whether any additional insight was gained in relation to
the model that included only age, family history and
menopausal status. To facilitate interpretation, the prior
and posterior odds used in the calculation of the Bayes
factors are reported along with the Bayes factors in
Table 3.
In the comparison of one model to all remaining ones,
w ef o u n dp o s i t i v ee v i d e n c ef o rt h en u l lm o d e l( B F all =
3.8) and for the model containing only NAT1 (BFall =
3.4). Very mild evidence was suggested for the single-
effect models of packyears (BFall =1 . 4 ) ,NAT2 (BFall =
1.3) and GSTT1 (BFall = 1.1). Very mild evidence was
Table 2 Selected results from logistic regression and BMA.
Variable Logistic regression BMA
Pointwise Modelmain
a Modelall
b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
& OR|I = 1 (95% CI)
$ Prpost BF(I =1 )
packyears 1.08 (1.00-1.16)* 1.08 (1.01-1.16)* 1.09 (1.01-1.17)* 1.01 (1.01-1.01) 1.08 (1.08-1.08) 0.13 0.43
NAT1 *10 1.21 (1.01-1.44)* 1.18 (0.98-1.42)
# 1.21 (1.00-1.46)
# 1.05 (1.05-1.05) 1.19 (1.19-1.20) 0.26 1.05
NAT2 slow vs fast
1 0.86 (0.70-1.04) 0.90 (0.73-1.11) 0.89 (0.72-1.09) 0.98 (0.98-0.98) 0.87 (0.87-0.88) 0.13 0.45
CYP1A1 *1
2 0.96 (0.77-1.21) 0.94 (0.74-1.18) 0.92 (0.73-1.16) 1.00 (1.00-1.00) 0.96 (0.96-0.97) 0.06 0.19
GSTT1 deletion 0.84 (0.65-1.10) 0.86 (0.66-1.12) 0.86 (0.66-1.13) 0.98 (0.98-0.98) 0.86 (0.86-0.86) 0.12 0.42
GSTM1 deletion 1.13 (0.93-1.37) 1.15 (0.94-1.40) 1.16 (0.95-1.42) 1.01 (1.01-1.01) 1.12 (1.12-1.13) 0.09 0.31
CYP1B1 *3 0.90 (0.78-1.03) 0.90 (0.78-1.04) 0.90 (0.78-1.04) 0.99 (0.99-0.99) 0.91 (0.90-0.91) 0.09 0.31
packyears × NAT2 1.19 (1.03-1.38)* 1.20 (1.03-1.40)* 1.00 (1.00-1.00) 1.19 (1.18-1.20) 0.01 0.30
packyears × GSTM1 1.11 (0.96-1.28) 1.11 (0.96-1.29) 1.00 (1.00-1.00) 1.10 (1.08-1.12) 0.00 0.07
Adjusted for age, menopause and family history
1 slow acetylators had at least one *4 allele
2 the reference was homozygote for the *1 allele
a only main effects
b all main effects and interactions
& OR and CI computed from mean coefficient estimate and its standard error averaged over all models
$ OR and CI computed from mean coefficient estimate and its standard error averaged over all models containing the respective variable
# p < 0.1, * p < 0.05
Table 3 Model results for selected models.
Model M Posterior
1 Prior
2 BFall
3 BF0
4
NULL 0.59 0.154 3.8 1.0
packyears 0.067 0.047 1.4 0.1
NAT1 0.159 0.047 3.4 0.3
NAT2 0.063 0.047 1.3 0.1
CYP1A1 0.024 0.047 0.5 0.0
GSTT1 0.054 0.047 1.1 0.1
GSTM1 0.038 0.047 0.8 0.1
CYP1B1 0.044 0.047 0.9 0.1
NAT1, GSTT1 0.021 0.015 1.4 0.0
NAT1, GSTM1 0.017 0.015 1.1 0.0
NAT1, CYP1B1 0.017 0.015 1.1 0.0
Adjusted for age, menopause and family history
1 obtained from MCMC-sampling
2 uses BMA parameters
3 support for M against all other models
4 support for M against null model
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GSTT1, GSTM1,a n dCYP1B1 (BFall =1 . 4 ,1 . 1 ,a n d1 . 1 ,
respectively). When taking into account interactions,
none of the models exhibited a Bayes factor greater than
1. The same was true for Bayes factors versus the null
model.
Sensitivity analysis
We investigated the sensitivity of our results to the
choice of priors by considering different values for the
prior hyperparameters described above. Specifically, we
varied the values of  12 main main , () and  12 int int , () in
the prior of pν =P r ( Iν = 1) to consider different
expected prior probabilities of model inclusion. More-
over, different specification of μint in the prior of ψint,a s
well as of the scale of the half-Cauchy prior for s
2, were
evaluated. Table 4 shows the different hyperparameter
choices.
Estimates of posterior odds ratios showed little varia-
tion for different expected prior values of pν.T h ep o s -
terior probability of model inclusion changed according
to the changes in the prior parameters, i.e. doubling the
prior probability of including an effect typically led to
twice the posterior probability of actually including it.
Varying the mean μint in the log-normal distribution
of ψint showed no effect on the results, neither did
choosing a different scale of the prior for s
2.
Discussion
Both logistic regression and BMA highlighted a signifi-
cant effect of NAT1. Furthermore, logistic regression
showed significant effects of packyears and of the inter-
action of packyears with NAT2 on breast cancer risk.
The role of NAT1 as strongest effect is supported by the
Bayesian analysis of selected models. Stepwise regression
analysis indicated the additional involvement of CYP1B1
and of the interaction of packyears and GSTM1 in
breast carcinogenesis.
On a biological level, NAT1 was initially implicated in
breast cancer susceptibility through a report of a posi-
tive association of the NAT1*11 allele with breast cancer
risk as well as combined effects with cigarette smoking
and meat consumption [10], which was, however, not
confirmed in a subsequent study [11]. The inconsistent
results could be attributed to sample size requirements
necessary for assessing effects of NAT1*11, which occurs
in approximately only 3% of the general population [12].
We studied the NAT1*10 allele, which occurs with
much greater frequency in the Caucasian population
than the NAT1*11 allele, and may be rapid acetylating.
NAT1*10 has been reported to be associated with higher
NAT1 activity in both bladder and colon tissue [13-15].
However, the association between the NAT1*10 allele
and increased NAT1 activity in vivo has not been con-
firmed in other studies [16-18]. For breast cancer, no
significant effect of NAT1*10 has been found in several
studies [10,11,19].
Detection of a gene effect with odds ratio in the order
of magnitude that we have found for NAT1 with 80%
power at a significance level of 0.05 (assuming allele fre-
quency 0.17, population risk 10%, log-additive disease
model and unmatched 1:2 case-control design) requires
1,088 cases and twice the number of controls [20]. Thus
the previous studies, as well as our own, would not have
enough power to consistently detect such an effect.
Our results from logistic regression analysis regarding
the association of NAT2 with breast cancer risk, as pre-
viously reported [4], are in line with findings from other
studies. In a meta- and pooled analysis including 13 stu-
dies, NAT2 was not independently associated with
breast cancer risk but smoking was found to be asso-
ciated with increased risk in NAT2 slow acetylators but
not in rapid acetylators [21].
The GSTM1 null genotype has not been found to con-
fer susceptibility to breast cancer [22]. However, smo-
kers carrying the GSTM1 null genotype were at
significantly elevated risk for breast cancer overall in a
meta-analysis of seven studies [23]. An earlier pooled
analysis of another seven smaller almost non-overlap-
ping studies, however, did not show clear effect modifi-
cation in the association between GSTM1 and smoking
[22]. Our results from stepwise regression showed a
non-significant effect modification by GSTM1,w i t h
higher risk of breast cancer associated with smoking
among those with the GSTM1 null genotype.
Results from regression and Bayesian analyses differed
in that univariate BMA analysis identified only NAT1 as
significant and did not yield significant findings for
packyears and the interaction of packyears and NAT2.
One possible explanation is that inference from BMA is
based on posterior and prior probabilities instead of p-
values. Thereby it avoids the problem of multiple com-
parisons inherent in pointwise testing of coefficients in a
logistic model. In fact, none of the findings from logistic
regression remain significant when Bonferroni-corrected
Table 4 Hyperparameter scenarios for the sensitivity
analysis.
Variation of pν:
E(pmain) 0.10 0.25 0.50
E(pint) 0.25 0.50 0.75
Variation of ψint:
μint 2.3 3.0 4.6
Variation of s
2:
scale(s
2) 25 100
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to-one correspondence between frequentist and Baye-
sian analyses, since the latter explicitly depend on the
specified priors. Our results were stable for different
hyperparameter choices. However, adequate prior speci-
fication always needs to be kept in mind before starting
any Bayesian analysis. In our case, mostly uninformative
prior distributions were specified to reflect the lack of
sufficient external information justifying an a priori dis-
tinction of variables. We therefore allowed the data
more weight versus prior information in estimation and
model selection. However, if desired, BMA provides a
framework for the explicit inclusion of biological prior
information, like pathway characteristics, into the analy-
sis through prior specification. If one is confident about
biological prior information, stronger prior assumptions
may be helpful to guide the analysis. However, bias will
be introduced at the same time, so that this trade-off
must be carefully considered.
Conclusions
The strength of BMA is its explicit statement of the
prior assumptions given by the prior distributions for
model parameters, and its consideration of model uncer-
tainty by obtaining results averaged over a multitude of
possible models. It evaluates single variables and a range
of models at the same time, yielding stabilized estimates
based on a set of potential data-generating models.
Moreover, it provides a means to reduce dimensionality
and avoids the problem of multiple comparisons.
In our study both BMA and regression analyses
yielded a significant effect of NAT1*10, while BMA atte-
nuated other significant findings from logistic regres-
sion. Since all Bayesian inference depends on the
specified prior information, prior choice must be care-
fully considered when conducting a Bayesian analysis.
Additional material
Additional file 1: WinBUGS code for the Bayes Model Averaging
analysis. The WinBUGS code for the Bayes Model Averaging analysis of
our data, along with all used parameters.
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